To identify a novel synthetic lethal target in SMARCB1-deficient cancers, we first established an isogenic cell line model by introducing SMARCB1 cDNA into SMARCB1-deficient JMU-RTK-2 rhabdoid tumor cells (Fig. 1a). This evidence concerns the gene SMARCB1 and cancer.